Jenoptik's Semi-Driven Acceleration: Order Intake Surge and a New Strategy Review
A New CEO and a Strategic Pause
Jenoptik's H1 2026 report came with a leadership twist. Dominic Dorfner, the physicist turned manager, joined as CEO on August 1, and he used his first earnings call to set a cautious tone on the company's ongoing Order intake strength while reminding investors that a full strategic review is underway. "I'm personally convinced that there is a great relevance of photonics for many industries we serve," he said, adding that "photonics is an attractive industry with a lot of growth potential." But he was also clear that the executive board would only communicate key findings "towards the end of the year at the earliest." That sets up a potential overhang of strategic uncertainty, even as the operational engine hums.
The Semi Cycle is Firing
The headline for the quarter is the record semi business momentum. Order intake at the group level rose more than 50% year-on-year, driven by "the ramp-up in the semi industry continues to be in full swing" and strong customer activity in both lithography and inspection. The company lifted its full-year guidance to the upper half of its initial ranges: revenue growth now 5-9% and EBITDA margin 20-21%. "We now expect to reach the upper half of the initial guided revenue range and EBITDA margin range," said Prisca Havranek-Kosicek, who remains on the board. The semi division posted an EBITDA margin of close to 32%, up sharply as the Dresden fab ramps and the product mix shifts toward higher-value inspection systems.
Crucially, the strength is not just inbound. The order backlog has ballooned to around EUR 825 million, a book-to-bill of 1.4. Management's focus has shifted from winning orders to execution and capacity. "The name of the game for the upcoming quarters, particularly in the OEM businesses is execution and output," Havranek-Kosicek noted. That means adding headcount, expanding the Jena classical optics facility, and pushing the Dresden ramp curve higher. The supply chain, so far, is keeping pace, but the team is wary of constraints as the whole semi ecosystem races to add capacity.
Biophotonics: Strength with a Caveat
The biophotonics business was a surprise contributor. Order intake jumped 45% year-on-year, helped by a multiyear medtech order in the low double-digit millions, strong defense demand, and some perceived early ordering ahead of geopolitical uncertainty. Yet management was deliberately cautious. "Don't extrapolate the biophotonics order intake for the future," warned Havranek-Kosicek, pointing to the lumpy, concentrated nature of the business. Revenues, however, still slipped ~5% due to a soft dental market, so the margin strength of ~22% was more a function of mix and lower costs than top-line growth.
The defense optics line sits within biophotonics and has become a strategic growth pillar. While order timing is unpredictable, the company is "fairly bullish on defense dynamics" given the global security environment. That aligns with the broader European defense spending theme, but Jenoptik's exposure is still modest relative to its semi business.
MPS and the Auto Drag
Not everything is glowing. The metrology and production solutions (MPS) unit remains loss-making, dragged by a "continued difficult market environment in the European automotive sector." Revenues were soft, but order intake improved, and the company expects a better second half due to seasonality and order conversion. Still, the guidance revision explicitly acknowledges "continuing weakness in automotive-related businesses," which caps the upgrades to the upper half rather than a full raise.
Capital Allocation and the Strategic Review
The bigger question is what the strategic review will do. Dorfner's arrival, combined with the usual CEO-transition review, often leads to portfolio reshaping. The company has already flagged Prodomax, a North American automation business, as a divestment candidate. "Nothing has changed on the strategic intent to divest this business over the course of time," said Havranek-Kosicek on the Q&A. The review could also address the optical data communications business, which is growing but small, and the company's positioning in the AI-driven photonics wave. optical data communications was mentioned as a commercial opportunity, but management deferred details to a future Capital Markets Day.
The Broader Picture
Jenoptik is not alone in benefiting from the photonics-driven semi upcycle. Other reporters this week—ACMR (semiconductor equipment), Coherent (COHR), and Lumentum (LITE)—all highlighted capacity expansion, high-power lasers, and optical connectivity. The global keyword list for the last 360 days is full of terms like "co packaged optics," "high bandwidth memory," and "data center interconnect." Jenoptik sits at the more esoteric end: lithography optics and inspection subsystems, not the sexy co-packaged modules. But its role is critical, and the strong order intake suggests customers are securing supply early.
The market has rewarded the operational beat, though the stock price data in our context is limited. The fundamental story is undeniable: revenue growth is back, margins are expanding, and backlog provides visibility. The key swing factor is the strategic review, which could unlock value through portfolio restructuring or could distract from execution if it drags on. For now, Jenoptik is a semi-cycle play with a strategy story—an increasingly rare combination in the mid-cap European tech space.